Shah Capital has ended its attempts to exert influence over vaccine developer Novavax, bringing more than years of activism ...

The immunology alliance follows a collaboration between the UK Biobank and the University of Exeter, supported by the Novo ...

Swiss biotech Nouscom has closed a €120 million ($135 million) fourth-round financing for a vaccine to protect people with a ...

On paper, the programme was built. In practice, many never crossed the finish line. Demand was not the problem. In a June ...

Pharmaceutical supply chains have more data at their fingertips than ever before. The challenge is turning that information into foresight. From temperature monitoring devices and connected containers ...

According to an update on the clinicaltrials.gov registry website, Novartis has terminated the study of Fabhalta (iptacopan) ...

There are rumours that a pharma 'mega-merger' – between AstraZeneca and Bristol Myers Squibb – is in the offing, ending several years without this type of deal. A report in the Financial Times ...

The EMA's human medicines committee, the CHMP, has recommended approval of Eli Lilly's oral GLP-1 agonist Foundayo for weight ...

City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a ...

August and September brought leadership changes across healthcare communications, consulting, investment, and industry ...

Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ...

From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...